Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition

Related Keywords

France ,Germany ,China ,Paris ,France General ,Switzerland ,Toronto ,Ontario ,Canada ,Thailand ,Belgium ,Saclay ,Cambridge ,Cambridgeshire ,United Kingdom ,Italy ,Israel ,Shanghai ,United States ,Canadian ,American ,America ,Canadians ,Jennifer Moore ,Amy Wolf ,Stewart Campbell ,Medison Pharma ,Binita Kamath ,Dara Willis ,Ipsen Euronext ,Intrahepatic Cholestasis ,Ioana Piscociu ,Nicolas Bogler ,Gastroenterol Hepatol ,Walter Perez ,Inbal Chen ,Gil Gurfinkel ,Division Head ,Corporate Communications ,Resource Network ,Gage Communications ,Global Corporate Communications ,Head Of Corporate Brand Strategy Communications ,Health Canada ,Progressive Familial Intrahepatic Cholestasis ,Executive Vice President ,North America ,Sick Children ,Serious Warnings ,Consider Bylvay ,Bylvay Product Monograph ,Product Monograph ,Rare Disease ,Sponsored Level ,American Depositary Receipt ,Investor Relations ,Relations Manager ,Corporate Brand Strategy ,Global Media Relations ,French Autorit ,Des March ,Universal Registration Document ,Learn About ,Accessed October ,Thailand Business ,